Regarding "Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era"
Marco Picardi, Claudia Giordano, Roberta Della Pepa, Novella Pugliese, Aldo Leone, Giuseppe Delle Cave, Rossella Iula, Fabrizio Pane, Giuseppe Gentile, Marco Picardi, Claudia Giordano, Roberta Della Pepa, Novella Pugliese, Aldo Leone, Giuseppe Delle Cave, Rossella Iula, Fabrizio Pane, Giuseppe Gentile
Abstract
This letter to the editor remarks on the article by Cheng et al., which reported results of a retrospective study that assessed 5‐year progression‐free and overall survival (OS) of 98 patients with hepatitis B surface antigen–seropositive patients receiving R‐CHOP‐21 as remission induction for diffuse large B‐cell lymphoma.
Trial registration: ClinicalTrials.gov NCT03804372.
Source: PubMed